The protease activated receptor-2 (PAR-2) belongs to a family of G-protein-coupled receptors that are activated by proteolysis. Trypsin cleaves PAR-2, exposing an N -terminal tethered ligand (SLIGRL) that activates the receptor. Messenger RNA (mRNA) for PAR-2 was found in guinea pig airway tissue by reverse transcription-polymerase chain reaction, and PAR-2 was found by immunohistochemistry in airway epithelial and smooth-muscle cells. In anesthetized guinea pigs, trypsin and SLIGRL-NH 2 (given intratracheally or intravenously) caused a bronchoconstriction that was inhibited by the combination of tachykinin-NK 1 and -NK 2 receptor antagonists and was potentiated by inhibition of nitric oxide synthase (NOS). Trypsin and SLIGRL-NH 2 relaxed isolated trachea and main bronchi, and contracted intrapulmonary bronchi. Relaxation of main bronchi was abolished or reversed to contraction by removal of epithelium, administration of indomethacin, and NOS inhibition. PAR-1, PAR-3, and PAR-4 were not involved in the bronchomotor action of either trypsin or SLIGRL-NH 2 , because ligands of these receptors were inactive either in vitro or in vivo , and because thrombin (a PAR-1 and PAR-3 agonist) did not show cross-desensitization with PAR-2 agonists in vivo. Thus, we have localized PAR-2 to the guinea-pig airways, and have shown that activation of PAR-2 causes multiple motor effects in these airways, including in vivo bronchoconstriction, which is in part mediated by a neural mechanism.
LIGR, with cleavage exposing a tethered ligand that binds to and activates the receptor (6) . Synthetic peptides corresponding to the tethered ligand domain (SLIGRL in the mouse and SLIGKV in humans) can activate PAR-2 without receptor cleavage. These hexapeptides in the amidated form of the COOH terminus retain maximum activity, although being about two or three orders of magnitude less active than trypsin (2, 8) .
PAR-2 has been localized to the human airways (10) . PAR-2 may be activated by tryptase (11, 12) , an enzyme released after mast cell degranulation and considered to play an important role in airway inflammation and hyperresponsiveness (13, 14) . In addition, PAR-2 is markedly upregulated after exposure to proinflammatory stimuli or cytokines (9) , which have been shown to play a critical role in chronic airway diseases. We therefore investigated whether PAR-2 was present in guinea pig airways and whether it had any functional relevance in these tissues.
In this study we examined the localization of PAR-2 in the guinea pig airways through reverse transcriptase-polymerase chain reaction (RT-PCR), and through immunohistochemistry with an antiserum that recognizes PAR-2 (15) . We also studied whether PAR-2 activation causes bronchomotor effects in guinea pigs in vivo and in vitro. We found that both trypsin and PAR-2-activating peptides caused bronchoconstriction in vivo and both bronchodilatation and bronchoconstriction in vitro. We also investigated the role of indirect mechanisms, including release of prostanoids, nitric oxide (NO), acetylcholine, histamine, bradykinin, and tachykinins in the bronchoconstriction produced by PAR-2 ligands. For this purpose, we used cyclooxygenase (COX) and NO synthase (NOS) inhibitors and antagonists for muscarinic, histamine H 1 , bradykinin B 2 (Hoe 140) (16) , and tachykinin-NK 1 (SR 140333) (17) and -NK 2 (SR 48968) (18) receptors.
METHODS

Animals
Male Hartley guinea pigs weighing 300 to 350 g were kept in a temperature-controlled environment with standard laboratory food and water freely available. Animals were anesthetized or euthanized with sodium pentobarbitone (60 to 100 mg/kg, intraperitoneally). Experimental procedures followed in the study were approved by the Committee on Animal Research of the University of Ferrara.
Detection of PAR-2 by RT-PCR
Total RNA was isolated from the trachea and colon of adult male guinea pigs through use of the RNAzol-reagent (Tel-Test Inc., Friendswood, TX). RNA (2.2 to 2.7 g for trachea, 0.5 g for colon) was reverse transcribed with random hexamers, using the GeneAmp RNA PCR kit (Perkin Elmer Cetus, Inc., Emeryville, CA). Oligonucleotide primers for guinea pig PARs were designed from the partial sequences obtained by cloning (N. W. Bunnett, unpublished data), as follows: PAR-2 forward: 5 Ј -CATGTTCAGCTACTTCCTCTCCTT-3 Ј , reverse: 5 Ј -GGTTTTA-ACACTGGTG GAGCTTGA-3 Ј ), and were chosen to amplify a 472-bp fragment. The PCR reaction included 2 l of the template complementary DNA (cDNA), 2.5 units of Taq DNA polymerase (Promega, Madison, WI), 1.5 mM MgCl 2 , 50 mM KCl, 0.1% (vol/vol) Triton X-100, and 0.2 mM each of deoxynucleotide triphosphates in 50 l of 10 mM Tris-HCl buffer, pH 9.0. The PCR conditions consisted of denaturation for 10 min, 35 cycles of replication at 94 Њ C for 1 min, 58 Њ C for 1.5 min, and 72 Њ C for 1 min, and a final elongation step at 72 Њ C for 10 min. Taq polymerase was added after the first denaturation step (hot start). Guinea pig colon was used as a positive control for the PCR reaction. As negative controls, water was used instead of RNA, or Taq polymerase was omitted. PCR products were analyzed by electrophoresis on a 1.2% agarose gel with ethidium bromide.
Detection of PAR-2 by Immunohistochemistry
Antiserum B5 to PAR-2 was raised in rabbits against a peptide fragment of rat PAR-2 ( 30 GPNSKGR ↓ SLIGRLDT 46 P-YGGC (where ↓ designates the trypsin cleavage site) (15) . Guinea pigs were anesthetized with sodium pentobarbital (60 mg/ kg intravenously) and were perfused transcardially with 50 ml of phosphate-buffered saline (PBS) containing 100 U of heparin, followed by perfusion with 500 ml of 4% paraformaldehyde in 100 mM PBS, pH 7.4. Immunohistochemistry was performed as previously described (15) . Briefly, trachea and bronchi were embedded in ornithyl carbamyltransferase compound (Miles, Elkhart, IN), and frozen sections (6 to 8 m) were prepared. Slides were incubated with B5 antiserum (1:1,000 to 1:2,000), whereas for controls the primary antiserum was incubated with the peptide used for immunization (1 M) before staining of tissues. Immunoreactivity was visualized with the unlabeled antibody-enzyme avidinbiotin complex (ABC; Vectastain, Burlingame, CA) technique. Labeled tissues were examined under an Axioplan microscope (Zeiss, Jena, Germany) with Nomarsky optics.
Measurement of Total Lung Resistance
Lung resistance (R L ) was measured according to a method reported previously (19) . Briefly, guinea pigs were anesthetized with sodium pentobarbital (45 mg/kg, intraperitoneally) and were then ventilated artificially through a tracheal cannula at a frequency of 60 breaths/ min. The tidal volume (V T ) was adjusted to maintain normal arterial blood gas tensions as described previously (19) . Airflow was monitored continuously with a pneumotachograph (A. Fleisch Medical, Inc., Richmond, VA) connected to a differential pressure transducer (Model DP45; Validyne Engineering Corp., Northridge, CA). Intratracheal pressure and esophageal pressure (Pes; as an approximation of pleural pressure) were measured. Transpulmonary pressure (Ptp; defined as the pressure difference between the intratracheal pressure and Pes) was measured with a differential pressure transducer (Model DP7; Validine). Output signals representing Ptp and airflow were recorded on a polygraph recorder (Model 1508 B Visicorder; Honeywell, Inc., Denver, CO). The right jugular vein and the left carotid artery were cannulated for drug administration and withdrawal of blood samples for arterial blood gas measurement, respectively.
Enzyme inhibitors were given at 5 min (captopril and phosphoramidon, 2. mol/kg) (all given intravenously at 15 min before the stimulus) were used at doses that have been shown to selectively block their respective receptors in guinea pigs (17, (19) (20) (21) . Desensitization to thrombin or SLI-GRL-NH 2 was obtained after three subsequent injections of each agonist at 20 min intervals, as reported previously for thrombin (22) . SLIGRL-NH 2 was given 20 min after the last thrombin administration, and vice versa . Preliminary experiments showed that aerosol administration (40 breaths) of the highest possible concentration (1 mM) of SLIGRL-NH 2 did not affect R L . In another set of experiments, PAR-2 ligands were instilled locally (in 50 l of 0.9% NaCl) into the tracheal lumen with a 30-gauge needle. Intratracheal instillation of 0.9% saline (50 l) caused an immediate (1 to 2 s after instillation) increase in R L (0.18 Ϯ 0.02 cm H 2 O/ml/s above baseline, n ϭ 8). Intratracheal instillation of drugs caused an early increase in R L (0.21 Ϯ 0.03 cm H 2 O/ml/s, n ϭ 8) similar to that caused by saline. Active drugs (trypsin or SLIGRL-NH 2 ) caused a delayed (10 to 30 s after instillation) increase in R L that was superimposed on the early increase. The effect of drugs instilled in the trachea was calculated as the increase in R L above the early increase.
Bronchomotor Responses In Vitro
Trachea, main bronchi, and second-order intrapulmonary bronchi were taken from guinea pigs killed by injection of pentobarbital (100 mg/kg, intraperitoneally). Tissues were mounted in 5-ml organ baths containing a modified Krebs solution (118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 0.5 mM MgCl 2 , 25 mM NaHCO 3 ,1 mM NaHPO 4 , and 11.1 mM glucose) maintained at 37 Њ C and oxygenated with a mixture of 95% O 2 and 5% CO 2 in the presence of captopril and phosphoramidon (both 1 M). An optimal tension of 1 g was applied to tissues fixed to the base of the organ bath and connected to an isometric force transducer (Unirecord; Basile, Comerio, Italy). During the initial stabilization period (30 min), tissues were washed three times. Motor responses (either contraction or relaxation) were expressed as a percentage of the contraction produced by carbachol (1 M). Cumulative concentration-response curves for peptides (0.01 to 10 M) or trypsin (0.1 to 100 nM) were constructed. Preliminary experiments showed that pretreatment with phosphoramidon and captopril (1 M each) had a tendency to increase motor responses (both relaxation and contraction) to PAR-2 agonists (data not shown). However, these increases did not reach the level of significance. Nevertheless, for consistency with in vivo experiments, the two peptidase inhibitors were always added in in vitro experiments ( see R ESULTS ).
The epithelial layer of the trachea and main bronchi was removed with a cotton swab. Histologic examinations of the tissues were performed as reported previously (23), and showed that the epithelial layer was completely removed, whereas no damage was observed to the lamina propria (data not shown).
Release Experiments
Trachea, main bronchi, and second-order intrapulmonary bronchi were taken from guinea pigs killed by injection of pentobarbital (100 mg/kg, intraperitoneally) and kept in a cold, oxygenated (96% O 2 -4% CO 2 ) Krebs solution of the following composition (mM): NaCl 119, NaHCO 3 25, KH 2 PO 4 1.2, MgSO 4 1.5, KCl 4.7, CaCl 2 2.5, glucose 11. Tissue slices (0.4 mm thick) were placed into thermostated (37 Њ C) 1-ml chambers and superfused at a rate of 0.4 ml/min with oxygenated Krebs solution containing 0.1% bovine serum albumin, 1 M phosporamidon, and 1 M captopril. After a 120-min stabilization period, 5-min fractions were collected (four baseline fractions and four fractions during exposure to the stimulus) into polypropylene tubes containing acetic acid (final concentration 2 N). At the end of the experiment, slices from each chamber were weighed. Fractions were freeze-dried, reconstituted with the assay buffer, and assayed for substance P-like immunoreactivity (SP-LI) content as reported previously (24) . The mean baseline value was subtracted from each value obtained during exposure to the stimulus.
Reagents
Mouse and human PAR-2-activating peptides (SLIGRL-NH 2 and SLIGKV-NH 2 , respectively), mouse and human PAR-2 reverse peptides (LRGILS-NH 2 and VKGILS-NH 2 , respectively), and PAR-4 (GYPGQV-NH 2 )-activating peptide were synthesized at the Laboratory of Pharmaceutical Chemistry of the University of Ferrara. Trypsin was purchased from Worthington Biochemical Co. (Freehold, NJ). Phosphoramidon, captopril, indomethacin, thrombin, pyrilamine, atropine, L -NMMA, D -NMMA, C apsaicin, and soybean trypsin inhibitor were purchased from Sigma Chemical Co. (St. Louis, MO). Hoe 140 was a gift of Dr. K. Wirth (Hoechst GmbH, Frankfurt, Germany) and SR 140333 and SR 48968 were gifts of Dr. X. Emonds-Alt (Sanofi, Montpellier, France). All drugs were dissolved in 0.9% saline except indomethacin, which was dissolved in ethanol and 0.9% saline (1:5 ratio [vol/vol]), and SR 48968 and SR 140333 (both 10 mM), which were dissolved in dimethylsulfoxide. The maximum amount of ethanol or dimethylsulfoxide injected did not modify the respiratory responses of guinea pigs. All drugs were freshly prepared for each experiment.
Statistical Analysis
Values are mean Ϯ SEM. Changes in R L are given as differences from baseline. R L values after intratracheal instillation are given as the difference between the delayed increase and the early increase in R L . Statistical analysis was done through one-way analysis of variance, and with Dunnett's test for multiple comparisons or with Student's t test for unpaired data. In all cases, a value of p Ͻ 0.05 was considered significant.
RESULTS
Detection of PAR-2 RNA in Tissues of Guinea Pig Trachea by RT-PCR
For RT-PCR, we used primers based on the partial cloning of guinea pig PAR-2 to determine whether PAR-2 messenger RNA (mRNA) was expressed in guinea pig airway tissue. A PAR-2 product of the predicted size of 472 bp was amplified after 35 cycles from this tissue (Figure 1 ). This band migrated identically to a PCR product from guinea pig colon, which was used as a positive control (Figure 1 ). The lower signal of PAR-2 in the colon as compared with the trachea can be explained by a lower concentration of colon RNA used for reverse transcription. PAR-2 RNA was not detected in negative controls.
Detection of PAR-2 by Immunohistochemistry
Immunoreactive PAR-2 was readily detected in several cell types in the trachea and bronchi of the guinea pig. In both the trachea and the bronchi, PAR-2 immunoreactivity was detected in epithelial cells (Figures 2A, 2D , and 2E); smooth muscle surrounding the trachea, bronchi, and blood vessels (Figures 2A and 2C through 2F); and endothelial cells ( Figures 2D and 2F) . Examination under high magnification revealed that PAR-2 immunoreactivity was prominent at the apical surface of epithelial cells (Figures 2A and 2E) , and was also present at the basolateral membrane ( Figure 2E ). PAR-2 was also detected in intracellular locations in epithelial cells. Staining was abolished when the PAR-2 antibody was preabsorbed with the receptor fragment that was used for immunization ( Figure 2B ).
Bronchoconstriction In Vivo
After a stabilization period of 60 min, baseline R L remained stable for at least 2 h. In naive guinea pigs, the baseline value of R L was 0.19 Ϯ 0.02 cm H 2 O/ml/s (n ϭ 6). Intravenous injection (1 ml/kg) of 0.9% NaCl did not change the baseline value of R L (data not shown). Injection of trypsin, SLIGRL-NH 2 , or SLIGKV-NH 2 caused a significant increase in R L ( Figure 3 and Table 1 ). Bronchoconstrictor responses to SLIGRL-NH 2 (1 mol/kg, intravenously) (0.33 Ϯ 0.06 cm H 2 O/ml/s, n ϭ 6) and to trypsin (50 nmol/kg, intravenously) (0.28 Ϯ 0.05 H 2 O/ ml/s, n ϭ 5) were significantly increased by pretreatment with phosphoramidon and captopril (0.51 Ϯ 0. Table 1 ) (all 10 mol/kg, intravenously) did not cause any change in baseline RL, whereas thrombin injection increased RL (Table 2) . At the third injection, response to the thrombin was reduced by more than 80%. After desensitization to thrombin, bronchoconstriction in response to SLIGRL-NH 2 (Table 2) or trypsin (50 nmol/kg, data not shown) was similar to that obtained after three injections of the vehicle. After desensitization to SLIGRL-NH 2 , obtained with three closely spaced administrations of this peptide, thrombin was still able to cause bronchoconstriction (Table 2).
Pretreatment with the NOS inhibitor L-NMMA Significantly increased the bronchoconstriction caused by intravenous trypsin and SLIGRL-NH 2 , as compared with the effects observed after pretreatment with the inactive enantiomer, D-NMMA (Table 1) . Pretreatment with indomethacin caused a significant decrease in the effect of trypsin and SLIGRL-NH 2 (Table 1) . Pretreatment with atropine, pyrilamine, or Hoe 140 did not affect bronchoconstriction caused by trypsin or SLI-GRL-NH 2 (data not shown). The combination of the tachykinin-NK 1 receptor antagonist SR 140333 and the tachykinin-NK 2 receptor antagonist SR 48968 markedly inhibited bronchoconstriction induced by intravenous trypsin or SLIGRL-NH 2 , without affecting bronchoconstriction induced by histamine (Table 1) .
Intratracheal instillation of trypsin (10 nmol) or SLIGRL-NH 2 (0. Intratracheal instillation of thrombin (20 U), or mouse PAR-2 reverse peptide (0.5 mol) did not cause any delayed increase in RL (data not shown).
Bronchomotor Effects In Vitro
After a stabilization period of 60 min, carbachol (1 M) contracted isolated guinea pig bronchi (2.15 Ϯ 0.23 g, n ϭ 9). In nonprecontracted bronchi, SLIGRL-NH 2 , SLIGKV-NH 2 (both at 0.1 to 10 M), or trypsin (0.1 to 100 nM) caused inconsistent changes in tone that were not investigated further. SLIGRL-NH 2 , SLIGKV-NH 2 (both at 0.1 to 10 M), or trypsin (0.1 to 100 nM) caused a concentration-dependent relaxation in carbachol-precontracted bronchi (Figures 3 and 4) . In about 50% of the tissues examined, trypsin (1 M) or SLIGKV-NH 2 (100 M) caused a contraction (15 to 22% of that with carbachol) after a first phase of relaxation (data not shown). In epithelium-denuded preparations, the relaxation produced by PAR-2-activating peptides or trypsin was either abolished or converted into a contraction after indomethacin or L-NMMA (Figure 4) . Atropine, pyrilamine, Hoe 140, or the combination of SR 14033 and SR 48968 (all 1 M, n ϭ 4 for each condition) did not affect either bronchorelaxation or bronchoconstriction induced by trypsin, SLIGRL-NH 2 , or SLIGKV-NH 2 (data not shown).
In isolated tracheal rings precontracted with carbachol (1 M), both trypsin (0.1 to 100 nM) and SLIGRL-NH 2 (0.1 to 10 M) caused a concentration-dependent relaxation ( Figures  3 and 5) . The relaxation was inhibited by removal of the epithelial layer, by indomethacin, and by L-NMMA ( Figure 5 ). In nonprecontracted tracheal rings, we obtained inconsistent results that were not further investigated. Thrombin and PAR-4-activating peptide did not affect the tone of either precontracted or nonprecontracted trachea or main bronchi (data not shown).
In second-order intrapulmonary bronchi precontracted with carbachol (1 M), both trypsin (0.1 to 100 nM) and SLIGRL-NH 2 (0.01 to 10 M) caused a moderate contraction that was not further investigated. In nonprecontracted intrapulmonary bronchi, trypsin (0.1 to 100 nM) and SLIGRL-NH 2 bronchi (data not shown). Trypsin (100 nM) treated with soybean trypsin inhibitor (10 mg/ml for 60 min) failed to affect the tone of tracheal and bronchial preparations (data not shown), indicating a requirement for enzymatic activity in activation.
SP-LI Release
Exposure of slices of guinea pig airways to SLIGRL-NH 2 (10 M) caused an increase in SP-LI outflow of 1.72 Ϯ 0.26 fmol/g/20 min above baseline. After preexposure to capsaicin (10 M for 20 min, at 60 min before the stimulus), a treatment that has been shown to desensitize primary sensory neurons (25) , the increase in SP-LI outflow induced by SLIGRL-NH 2 (10 M) was significantly lower (0.38 Ϯ 0.11 fomol/g/20 min, n ϭ 6, p Ͻ 0.05). The increase in SP-LI outflow induced by LRGILS-NH 2 (10 M) was negligible and significantly different (0.13 Ϯ 0.09 fomol/g/20 min, n ϭ 6, p Ͻ 0.05) from that induced by SLIGRL-NH 2 .
DISCUSSION
In Vivo Bronchoconstriction by PAR-2 Ligands
In the present study, intravenous or intratracheal administration of trypsin and two different PAR-2-activating peptides caused bronchoconstriction in guinea pigs in vivo, whereas PAR-2 reverse peptides were inactive. PAR-4-activating peptide was also inactive, therefore excluding a role for this receptor in bronchoconstriction. Thrombin was recently shown to cause bronchoconstriction in guinea pigs via a platelet-dependent mechanism (22) . This effect of thrombin underwent desensitization after repeated thrombin administration (22) . In the current study, desensitization to thrombin did not reduce the ability of SLIGRL-NH 2 or trypsin to cause bronchoconstriction. Conversely, after desensitization to SLIGRL-NH 2 , the ability of thrombin to cause bronchoconstriction was unaffected. These findings exclude a role of PAR-1 and PAR-3 (both activated by thrombin) in bronchoconstriction induced by PAR-2 ligands. Our results therefore indicate that bron- choconstriction induced in vivo by trypsin, SLIGRL-NH 2 , and SLIGKV-NH 2 is mediated by PAR-2 or by an unidentified receptor with similar sensitivity to trypsin and PAR-2-activating peptides.
Studies with COX and NOS inhibitors showed that bronchoconstriction induced by trypsin and SLIGRL-NH 2 was in part mediated by prostanoids and could be inhibited by NO. Studies with receptor antagonists indicated that this effect of trypsin and SLIGRL-NH 2 was independent of the generation of kinins, the release of histamine from mast cells, and the release of acetylcholine from postganglionic cholinergic nerves. In contrast, the marked reduction by the combination of tachykinin-NK 1 and -NK 2 receptor antagonists, of the bronchoconstriction caused by PAR-2 ligands indicated that tachykinin release from sensory nerves was involved in this bronchoconstriction. This hypothesis is strongly supported by the observation that SLI-GRL-NH 2 , but not the reverse peptide LRGILS-NH 2 , caused a capsaicin-sensitive release of substance P (SP) from slices of guinea-pig airways. Tachykinins released from sensory nerve terminals are powerful bronchoconstrictors, and tachykinin-induced bronchoconstriction in guinea pigs is mediated by both NK 1 and NK 2 receptors (19) . Previous studies have shown that a variety of mediators cause the release of tachykinins from sensory nerves (25) . Data from the present study indicate PAR-2 activation is an additional mechanism that promotes bronchoconstriction via tachykinin release from sensory nerve endings.
In Vitro Bronchomotor Effects of PAR-2 Ligands
The motor action of PAR-2 in guinea pig airways results from the activation of multiple pathways. The prominent in vitro effect of trypsin, SLIGRL-NH 2 , and SLIGKV-NH 2 observed in our study was an epithelium-, NO-, and prostanoid-dependent relaxation of trachea and main bronchi. After removal of the relaxing factors (epithelium, NO, and prostanoids), a moderate contraction was produced in main bronchi. In smaller intrapulmonary bronchi, the sole effect of trypsin and SLIGRL-NH 2 was airway smooth-muscle contraction, which was independent of tachykinin, histamine, acetylcholine, or ki- nin release. RT-PCR showed the presence of PAR-2 in the airway tissue. More importantly, immunohistochemistry showed localization of PAR-2 to airway epithelial and smooth-muscle cells. Thus, it is possible that direct activation of PAR-2 on smooth muscle causes contraction of isolated bronchi. Small intrapulmonary airways are likely to contribute more than larger airways to resistance to flow in the lungs. In vivo and in vitro experiments suggest that modulation of bronchomotor tone in vivo by PAR-2 depends more strongly on indirect bronchoconstrictor mechanisms (sensory nerve activation and release of prostanoids) and direct smooth-muscle contraction of intrapulmonary bronchi than on bronchodilatation produced in the trachea and main bronchi.
Protective or Detrimental Role of PAR-2
During completion of the present study, Cocks and colleagues reported (26) that PAR-2 activation mediates an epitheliumand prostanoid-dependent relaxation in mouse isolated bronchi, and that both trypsin and PAR-2 peptidomimetics produced a moderate relaxation in isolated guinea pig bronchi (26) . PAR-2 activation also inhibited serotonin-induced bronchoconstriction in rats in vivo (26) . On the basis of these data, Cocks and colleagues (26) proposed that PAR-2 had a prostanoid (prostaglandin E 2 )-dependent bronchoprotective role in the airways. We also observed a pronounced, indomethacin-sensitive relaxation of mouse trachea by trypsin and mouse PAR-2-activating peptide (F. Van Noouten and P. Geppetti, unpublished observations). However, in mouse and rat airways, a number of mediators, including SP (via NK 1 receptors) (27) and bradykinin (via B 2 receptors) (28) produce epithelialand prostanoid-dependent bronchorelaxation. However, SP and bradykinin are powerful bronchoconstrictors in guinea pig and human airways (25, 29) . Additionally, tachykinin NK 1 receptor stimulation causes a prostanoid-dependent relaxation of the isolated mouse bronchus (27) and a prostanoid-dependent contraction of the isolated small human bronchus (30) . Thus, the guinea pig model, rather than the mouse model, seems to better reflect the role of mediators like bradykinin and tachykinins in the human airways.
We routinely used peptidase inhibitors, whereas these drugs were not used in the experiments done by Cocks and colleagues (26) . However, this factor cannot be the reason for the different results obtained, because peptidase inhibitors did not qualitatively change the motor responses to PAR-2 agonists in guinea pigs but affected only the quantitative magnitude of in vivo bronchoconstriction. The present data from guinea pigs show that PAR-2 activates different bronchomotor mechanisms that may or may not be protective. PAR-2 activation stimulates bronchoconstriction that is in part neurally mediated and in part likely to be caused by direct airway smooth-muscle contraction. PAR-2 also activates an epithelial-, NO-, and prostanoid-dependent bronchodilator pathway. These multiple roles of PAR-2 bear some similarity to the different effects produced by bradykinin. Bradykinin, via B 2 -receptor activation, causes an epithelial-, NO-, and prostanoiddependent bronchodilatation (23, 31) as well as an indirect, neurally mediated bronchoconstriction (32) . In addition, as observed in the present study with PAR-2 agonists, indomethacin inhibits about 50% of the bronchoconstriction induced by intravenous bradykinin, but not that induced by intratracheal bradykinin (25) . A possible explanation for this differential response is that bradykinin injected into the blood stream releases bronchoconstrictor prostanoids, whereas with bradykinin applied locally in the airways, the bronchomotor role of prostanoids, if any, is negligible (25) . The contractile action of PAR-2 agonists in vitro is also similar to that of bradykinin, which contracts isolated guinea-pig bronchi in a manner that is independent of sensory nerve activation and which apparently occurs through a direct effect on smooth-muscle cells (25) . These interpretations may also apply to the bronchomotor effects produced by PAR-2 agonists.
The bronchocomotor effects of bradykinin in humans resemble those described in guinea pigs. In humans, bradykinininduced bronchoconstriction is mediated indirectly by neural mechanisms (25, 33) and is limited by an NO-dependent bronchodilator pathway (34) . If the PAR-2-mediated responses found in guinea pigs are present in human airways, PAR-2 stimulation in severe asthma, a condition associated with epithelial damage, might promote bronchoconstriction rather than protective bronchodilatation.
The observation that trypsinogen and PAR-2 colocalize to the human airway epithelium has suggested the interesting hypothesis that PAR-2 acts in a paracrine manner to promote protective bronchodilatation in the airway mucosa (26) . Localization of PAR-2 to the airway smooth muscle, and its ability to stimulate sensory nerves, explain its bronchoconstrictor effect in guinea pigs. In addition to trypsin released from the epithelium, other agonists may stimulate PAR-2 in the airways. Tryptase released from mast cells during anaphylaxis or other inflammatory processes (13, 14) might stimulate epithelial and extraepithelial PAR-2. Protease activity is present in house dust mite extracts. In particular, the allergen contained in the house dust mite Dermatophagoides pteronyssinus is a trypsinlike enzyme (35) . Thus, the hypothesis may be considered that inhaled allergens having protease activity cause PAR-2-mediated bronchocomotor effects in allergic asthma.
